However, incurable castration resistant prostate cancer (CRPC) develops resistance mechanisms to cope with trace amounts of androgen including AR overexpression and mutation in the AR ligand binding domain.METHODSThe CRPC cell model VCaP derivative of a prostate cancer bone metastasis was used in ...
The study, published on January 7, 2015, in Science Translational Medicine, examined 16 men with metastatic prostate cancer who had been receiving testosterone-lowering treatment to which their cancers were growing resistant. The men were given three 28-day cycles of an intramuscular testosteron...
In recent years, clinicians have begun treating patients with late-stage, therapy resistant prostate cancers using a monthly, high-dose injection of testosterone in a technique called bi-polar androgen therapy, or BAT. The inability to understand how this intervention works has hindered its widespread...
This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other places is the body (metastatic). Bipolar androgen therapy is the regulatio...
Munich, Germany: A strategy of alternately flooding and starving the body of testosterone is producing good results in patients who have metastatic prostate cancer that is resistant to treatment by chemical or surgical castration, according to new findin
The WOMBAT study will test if BAT can prolong the time it takes for nmCRPC prostate cancer to become detectable in other areas of the body (metastatic disease).Approximately 69 participants over the age of 18 with castrate resistant prostate cancer, no evidence of metastatic disease (M0) on co...
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results Background Enzalutamide is an androgen receptor inhibitor with a demonstrated overall survival benefit in metastatic castration-resistant prostate cancer. ... B Tomb...
Laboratory studies suggest that castration-resistant prostate cancer (CRPC) cell growth is suppressed by supraphysiologic doses of testosterone (T). In this study, 12 men received high doses of T transdermally for 7 d, for 4 mo, or until progression.The approach was safe and toxicity was ...
For many years, a level of 50 ng/dL was considered appropriate to halt the progression of the disease and prevent the development of castration-resistant prostate cancer. However, studies have suggested that lower testosterone levels are associated with prolonged survival, and that levels between 20...
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407–15. Article CAS Google Scholar Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum ...